The IPO eliminates the immediate going-concern risk and provides ~2 years of operating runway. Watch for the Q4 2026 end-of-Phase 1 meeting with FDA for BH-30643 in C797S-resistant NSCLC, which is the key near-term catalyst. Post-IPO shares (30.6M base) plus the ~1.5M IPO option grant shares and 5.3M reserved 2026 Plan shares mean material dilution overhang on top of the 30.6% float sold in the IPO.
Executive Summary
BlossomHill Therapeutics priced its IPO of 9,375,000 shares at $16.00 per share, raising $150 million in gross proceeds ($139.5 million net before expenses). The offering closed on August 6, 2026, with shares trading on Nasdaq under 'BLSM'. Net proceeds (~$134.9M) will fund clinical development of BH-30643 (OMNI-EGFR) in C797S-resistant NSCLC, BH-30236 (CLK inhibitor) in AML/HR-MDS, and IND-enabling work for BH-501284 (pan-KRAS). The company had a going-concern warning before the IPO, which this offering is intended to resolve.
Key Financial Metrics
Key Facts
- IPO of 9,375,000 shares at $16.00/share for gross proceeds of $150,000,000
- Net proceeds to company: ~$134.9M ($139.5M before estimated offering expenses)
- 30-day greenshoe option for up to 1,406,250 additional shares
- Shares to be outstanding after IPO: 30,643,660 (32,049,910 if greenshoe exercised)
- Underwriters: J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital, H.C. Wainwright & Co.
- Proceeds allocated: ~$70M for BH-30643, ~$20M for BH-30236, ~$15M for BH-501284, remainder for working capital
- Pre-IPO cash: $116.0M as of March 31, 2026; pro forma as-adjusted cash: ~$253.6M
- Pre-IPO accumulated deficit: ~$156.0M; 2025 net loss: ~$60.6M
- Pre-IPO auditor going-concern opinion; management estimates runway into Q1 2028 with IPO proceeds
- Underwriting discount: $1.12/share or $10.5M total; underwriters expect delivery August 10, 2026
Financial Impact
IPO raises $150M gross ($134.9M net); extends cash runway into Q1 2028 from pre-IPO $116M cash balance
Risk Factors
- Clinical-stage company with no approved products or revenue; high development risk across all three candidates
- Significant ongoing losses ($21M in Q1 2026 alone) and need for substantial additional capital beyond this IPO to complete clinical development
- Heavy reliance on BH-30643 C797S-resistant NSCLC program, which faces a competitive landscape with multiple investigational agents and no regulatory precedent for this specific mutation
- Initial investors hold 69.4% of post-IPO shares, concentrated ownership and potential future selling pressure
- Substantial dilution: existing shares (21.3M) vs. IPO shares (9.4M); plus option overhang of ~3.0M shares and 5.3M reserved for future equity plans
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001193125-26-340215 |
| Document: 0001193125-26-340215-index-headers.html | 0001193125-26-340215 |
| Document: 0001193125-26-340215-index.html | 0001193125-26-340215 |
| Document: 0001193125-26-340215.txt | 0001193125-26-340215 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 29d ago | Press Release | $21.34 $16.39 | ▲ +23.20% | ▲ +23.16% | $15.76 (+26.15%) |
Sep 18, 2026 5w ago | 8-K | $25.74 $13.94 | ▲ +45.84% | ▲ +46.05% | $15.76 (+38.77%) |
Sep 18, 2026 5w ago | Press Release | $25.74 $13.94 | ▼ −45.84% | ▼ −46.05% | $15.76 (−38.77%) |
Sep 15, 2026 6w ago | 8-K | $22.17 $15.48 | ▼ −30.18% | ▼ −33.15% | $15.76 (−28.91%) |
Aug 12, 2026 10w ago | Insider Cluster | $16.35 $20.86 | ▲ +27.58% | ▲ +29.33% | $15.76 (−3.61%) |
Aug 10, 2026 11w ago | Insider Cluster | $16.52 $22.00 | ▲ +33.17% | ▲ +34.23% | $15.76 (−4.60%) |
Aug 10, 2026 11w ago | 8-K | $16.52 $22.00 | ▲ +33.17% | ▲ +34.23% | $15.76 (−4.60%) |
Aug 7, 2026 11w ago | 424B4 | $15.99 $22.93 | ▲ +43.40% | ▲ +44.32% | $15.76 (−1.44%) |
Aug 7, 2026 11w ago | EFFECT | $16.00 $22.01 | ▲ +37.56% | ▲ +37.96% | $15.76 (−1.50%) |
Aug 6, 2026 11w ago | 3 | $16.00 $22.01 | ▲ +37.56% | ▲ +37.96% | $15.76 (−1.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers